

# Filomena Morisco

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6730820/filomena-morisco-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149  
papers

3,862  
citations

31  
h-index

57  
g-index

160  
ext. papers

4,918  
ext. citations

5.3  
avg, IF

4.69  
L-index

#	Paper	IF	Citations
149	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 394, 2184-2196	4.0	425
148	Dietary antioxidant compounds and liver health. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2004</b> , 44, 575-86	11.5	208
147	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 471-483	3.3	179
146	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2417-2429	4.0	176
145	Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. <i>Hepatology</i> , <b>2010</b> , 52, 1652-61	11.2	157
144	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 617-24	13.4	129
143	Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. <i>Journal of Hepatology</i> , <b>2001</b> , 35, 568-74	13.4	114
142	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 333-41	13.4	84
141	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002006	11.6	81
140	Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 1925-9	5.6	79
139	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , <b>2017</b> , 37, 514-528	7.9	71
138	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , <b>2018</b> , 67, 1784-1796	11.2	65
137	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 65-71	13.4	63
136	Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. <i>Transplantation</i> , <b>2006</b> , 81, 1532-41	1.8	61
135	The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. <i>European Journal of Endocrinology</i> , <b>2002</b> , 146, 743-9	6.5	58
134	Use of N,N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma. <i>Free Radical Research</i> , <b>2002</b> , 36, 869-73	4	56
133	Sustained virological response: a milestone in the treatment of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 2793-8	5.6	55

132	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , <b>2017</b> , 37, 1157-1166	7.9	53
131	Long-term safety of anti-TNF- $\alpha$ in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 273-6	3.9	53
130	Silibinin Restores NAD <sup>+</sup> Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver. <i>Nutrients</i> , <b>2017</b> , 9,	6.7	53
129	Rapid "breath-print" of liver cirrhosis by proton transfer reaction time-of-flight mass spectrometry. A pilot study. <i>PLoS ONE</i> , <b>2013</b> , 8, e59658	3.7	53
128	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , <b>2017</b> , 37, 259-270	7.9	50
127	Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease. <i>Translational Research</i> , <b>2014</b> , 163, 593-602	11	45
126	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. <i>Cancer</i> , <b>2014</b> , 120, 2150-7	6.4	45
125	Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy?. <i>Journal of Hepatology</i> , <b>1998</b> , 28, 390-5	13.4	42
124	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 455-467	3.3	41
123	Foods and liver health. <i>Molecular Aspects of Medicine</i> , <b>2008</b> , 29, 144-50	16.7	38
122	Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. <i>World Journal of Gastroenterology</i> , <b>2018</b> , 24, 2582-2595	5.6	35
121	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , <b>2017</b> , 37, 423-433	7.9	34
120	Garlic extract prevents CCl <sub>4</sub> -induced liver fibrosis in rats: The role of tissue transglutaminase. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 571-7	3.3	33
119	Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: Tail of a cohort infected in past decades. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 291-297	19.7	31
118	Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43 Suppl 1, S40-8	3.3	28
117	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185728	3.7	28
116	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , <b>2019</b> , 39, 1478-1489	7.9	27
115	Dietary trans-resveratrol bioavailability and effect on CCl <sub>4</sub> -induced liver lipid peroxidation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 618-22	4	27

114	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 292	8.5	26
113	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 1105-1114	3.3	26
112	Current evidence in the field of the management with TNF- $\alpha$ inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 641-50	5.4	26
111	Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1066-71	3.3	25
110	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , <b>2019</b> , 11,	6.6	25
109	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , <b>2021</b> , 41, 585-597	5.7	25
108	Coffee and liver health. <i>Journal of Clinical Gastroenterology</i> , <b>2014</b> , 48 Suppl 1, S87-90	3	24
107	Garlic extract attenuating rat liver fibrosis by inhibiting TGF- $\beta$ . <i>Clinical Nutrition</i> , <b>2013</b> , 32, 252-8	5.9	24
106	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 597-600	13.4	23
105	AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 120-37	3.3	23
104	Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2019</b> , 2019, 8742075	6.7	23
103	Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 200-8	3.4	23
102	Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 16-21	13.4	23
101	Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 3516-24	5.6	23
100	Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. <i>Therapeutics and Clinical Risk Management</i> , <b>2014</b> , 10, 493-504	2.9	22
99	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , <b>2019</b> , 39, 1852-1859	7.9	21
98	Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 129-138	1.6	21
97	Analysis of breath by proton transfer reaction time of flight mass spectrometry in rats with steatohepatitis induced by high-fat diet. <i>Journal of Mass Spectrometry</i> , <b>2012</b> , 47, 1098-103	2.2	21

96	Prevalence of hepatitis C virus infection in the household contacts of patients with HCV-related chronic liver disease. <i>Infection</i> , <b>1994</b> , 22, 183-6	5.8	21
95	Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 3013-3019	4	20
94	Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. <i>BMC Gastroenterology</i> , <b>2014</b> , 14, 214	3	20
93	Osteoporosis across chronic liver disease. <i>Osteoporosis International</i> , <b>2016</b> , 27, 1967-77	5.3	20
92	Oxidative status in chronic hepatitis C: the influence of antiviral therapy and prognostic value of serum hydroperoxide assay. <i>Free Radical Research</i> , <b>2004</b> , 38, 573-80	4	19
91	Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis. <i>Clinical Endocrinology</i> , <b>2003</b> , 58, 207-12	3.4	19
90	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , <b>2018</b> , 22, 859-871	3.3	17
89	Dietary supplementation of vitamin D prevents the development of western diet-induced metabolic, hepatic and cardiovascular abnormalities in rats. <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 1056-1064	5.3	17
88	Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 38, 68-72	3.9	16
87	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , <b>2018</b> , 68, 1232-1244	11.2	15
86	Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma. <i>Targeted Oncology</i> , <b>2017</b> , 12, 61-67	5	15
85	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 860-8	3.3	14
84	HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1022-1028	3.3	13
83	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 427-434	18.8	13
82	Application of PTR-TOF-MS to investigate metabolites in exhaled breath of patients affected by coeliac disease under gluten free diet. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2014</b> , 966, 208-13	3.2	13
81	Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 198-206	3.1	12
80	Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. <i>Liver International</i> , <b>2013</b> , 33, 1420-7	7.9	12
79	Tomato-based functional food as interferon adjuvant in HCV eradication therapy. <i>Journal of Clinical Gastroenterology</i> , <b>2004</b> , 38, S118-20	3	12

78	Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case report. <i>In Vivo</i> , <b>2013</b> , 27, 527-9	2.3	12
77	Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 1123-1130	4	11
76	Determination of plasma alpha-glutathione S-transferases in patients with HCV-related chronic infection: its significance and possible clinical relevance. <i>Liver</i> , <b>1998</b> , 18, 166-72		11
75	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 340-349	13.4	11
74	PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	11
73	Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 2138-2143	19.7	9
72	The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	9
71	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	9
70	Efficacy of loco-regional ablation therapy of HCC in a population of liver transplanted patients. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 1131-7	4	9
69	Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C. <i>Current Pharmaceutical Design</i> , <b>2002</b> , 8, 977-80	3.3	9
68	Use of Telemedicine for Chronic Liver Disease at a Single Care Center During the COVID-19 Pandemic: Prospective Observational Study. <i>Journal of Medical Internet Research</i> , <b>2020</b> , 22, e20874	7.6	9
67	The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 434-437	3.3	9
66	Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	9
65	Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2017</b> , 77, 448-453	2	8
64	A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 846-855	3.4	8
63	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 818-25	3.3	8
62	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 572-581	13.4	8
61	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.. <i>Gut</i> , <b>2021</b> ,	19.2	8

60	Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 867	5.6	7
59	Variation in genes encoding for interferon $\beta$ and $\beta 4$ in the prediction of HCV-1 treatment-induced viral clearance. <i>Liver International</i> , <b>2014</b> , 34, 1369-77	7.9	7
58	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , <b>2021</b> , 41, 396-407	7.9	7
57	Prevalence of and risk factors for HBV infection in a metropolitan Southern Italian area: Evidence for the effectiveness of universal Hepatitis B vaccination. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1257-1263	3.3	6
56	Decreasing role of HCV and HBV infections as aetiological factors of hepatocellular carcinoma in Italy. <i>Infection</i> , <b>2019</b> , 47, 805-810	5.8	6
55	Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. <i>Cancer Biomarkers</i> , <b>2020</b> , 29, 189-196	3.8	6
54	Chronic hepatitis C long-term responders to human leukocyte interferon-alpha therapy: persistence of a sustained biochemical and virological response during 5 years of surveillance. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1998</b> , 10, 399-403	2.2	6
53	Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life. <i>BioMed Research International</i> , <b>2018</b> , 2018, 8953581	3	6
52	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1011-1019	3.3	6
51	Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 941-947	3.4	5
50	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , <b>2018</b> , 38, 2028-2039	7.9	5
49	PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e53	13.4	5
48	Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185710	3.7	5
47	Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. <i>Oncotarget</i> , <b>2018</b> , 9, 17483-17490	3.3	5
46	Gut microbiota and functional diseases of the gastrointestinal tract. <i>Minerva Gastroenterology</i> , <b>2017</b> , 63, 355-372	3	5
45	The association between education level and chronic liver disease of any etiology. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 75, 55-59	3.9	5
44	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13542	4.6	5
43	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , <b>2020</b> , 14, 362-372	8.8	5

42	Metabolic-associated fatty liver disease (MAFLD) in coeliac disease. <i>Liver International</i> , <b>2021</b> , 41, 788-798	7.9	5
41	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. <i>International Journal of Biological Markers</i> , <b>2021</b> , 36, 54-61	2.8	5
40	Low influenza vaccination coverage in subjects with liver cirrhosis. An alert waiting for winter season 2020-2021 during the COVID-19 pandemic. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 2446-2452	19.7	5
39	A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro. <i>Viruses</i> , <b>2020</b> , 12,	6.2	4
38	Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 427-34	3.4	4
37	PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 734847	4.9	4
36	Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy. <i>Reviews on Recent Clinical Trials</i> , <b>2016</b> , 11, 306-316	1.2	4
35	Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
34	Hepatitis C Virus Clearance in Older Adults. <i>Journal of the American Geriatrics Society</i> , <b>2018</b> , 66, 85-91	5.6	4
33	Geographical pattern of chronic liver diseases in Italy: Results from two pooled national surveys. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 61, 40-43	3.9	3
32	Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 225-237	5.3	3
31	A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.. <i>Hepatology</i> , <b>2021</b> ,	11.2	3
30	The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	3
29	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 612-619	3.3	3
28	Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2021</b> , 40, 607-614	5.3	3
27	Characteristics and Changes over Time of Alcohol-Related Chronic Liver Diseases in Italy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 2018, 9151820	2.8	3
26	Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	3
25	HepaDisk - A new quality of life questionnaire for HCV patients. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1008-1015	3.3	2



24	Liver stiffness assessment by transient elastography suggests high prevalence of liver involvement in common variable immunodeficiency. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1599-1603	3.3	2
23	Hepatitis B vaccine coverage and risk factors for lack of vaccination in subjects with HBsAg negative liver cirrhosis in Italy: still, much work should be done. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1315-1319	3.3	2
22	Vitamin D levels and chronic hepatitis C. <i>E-SPEN Journal</i> , <b>2013</b> , 8, e169-e174		2
21	Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. <i>Journal of Medical Virology</i> , <b>2015</b> , 87, 1368-76	19.7	2
20	Etiology of and risk factors for transient and persistent aminotransferase elevation in a population of virus-free blood donors: a multicentre study. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 441-5	3.3	2
19	Basal core-IgM antibodies to hepatitis C virus are not predictive of successful alpha-interferon therapy. <i>Journal of Hepatology</i> , <b>1995</b> , 22, 377	13.4	2
18	Plasma phospholipid dysregulation in patients with cystathionine-β-synthase deficiency. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2020</b> , 30, 2286-2295	4.5	2
17	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1355-1366	13.4	2
16	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , <b>2021</b> ,	3.3	2
15	Ultrasound-based transient elastography improves the detection of liver disease in common variable immunodeficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 2507-2508	5.4	1
14	Effect of Red Wine Polyphenols on the Expression of Transthyretin in Murine Choroid Plexus. <i>Current Pharmaceutical Biotechnology</i> , <b>2016</b> , 17, 1008-15	2.6	1
13	Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study. <i>Liver Cancer International</i> , <b>2020</b> , 1, 12-24	0.8	1
12	The interpretation of liver function tests in pregnancy. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2020</b> , 44-45, 101667	2.5	1
11	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
10	Recalibrating survival prediction among patients receiving trans-arterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , <b>2021</b> , 2, 45-53	0.8	1
9	, and Extracts Modulate the Insulin Receptor Expression and Improve Hepatic Steatosis in NAFLD Patients: A Pilot Clinical Trial. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	1
8	Hepatitis C virus infection in end stage renal disease and after kidney transplant. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2014</b> , 23, 340-2	1.4	1
7	COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre study.. <i>Scientific Reports</i> , <b>2022</b> , 12, 4831	4.9	1

6	Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 925	3.6	o
5	Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment. <i>Journal of Hepatology</i> , <b>2020</b> , 73, S738	13.4	
4	It is futile to use interferon in HCV-related chronic hepatitis with viremia levels above 3 x 10(6) eq/ml. <i>Infection</i> , <b>1997</b> , 25, 190-1	5.8	
3	Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 824879	5.6	
2	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 133-143	7.5	
1	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1603-1609	3.3	